A new risk score for patients after first recurrence of stage 4 neuroblastoma aged ≥18 months at first diagnosis

A new risk score for patients after first recurrence of stage 4 neuroblastoma aged ≥18 months at first diagnosis

Abstract Background The prognosis of patients with recurrences from stage 4 neuroblastoma is not uniformly dismal. The evaluation of new therapies therefore needs to consider the individual risks of the treated patients. This study aims to define clinically useful risk criteria. Patients and Methods...

Full description

Bibliographic Details
Main Authors: Kiana Kreitz, Angela Ernst, René Schmidt, Thorsten Simon, Matthias Fischer, Ruth Volland, Barbara Hero, Frank Berthold
Format: Article
Language:English
Published: Wiley 2019-12-01
Series:Cancer Medicine
Subjects:
clinical trial
high‐risk neuroblastoma
recurrence
relapse
risk score
time‐dependent variable
Online Access:https://doi.org/10.1002/cam4.2562

Internet

https://doi.org/10.1002/cam4.2562

Similar Items